TG Therapeutics, Inc. Announces Follow-Up Data from the Chemo-Free Triple Combination of TG-1101, TGR-1202, and Ibrutinib at the ...
100% ORR (19 of 19) observed in patients with CLL/SLL, including 32% CR rate 100% ORR (6 of 6) observed in patients with MZL and MCL, with 50% CR rate 80% ORR (4 of 5) observed in patients with FL, with 20% CR rate Favorable safety profile observed in …